141 related articles for article (PubMed ID: 3840949)
1. The biochemical pharmacology of CI-920, a structurally novel antibiotic with antileukemic activity.
Jackson RC; Fry DW; Boritzki TJ; Roberts BJ; Hook KE; Leopold WR
Adv Enzyme Regul; 1985; 23():193-215. PubMed ID: 3840949
[TBL] [Abstract][Full Text] [Related]
2. Anticancer activity of the structurally novel antibiotic Cl-920 and its analogues.
Leopold WR; Shillis JL; Mertus AE; Nelson JM; Roberts BJ; Jackson RC
Cancer Res; 1984 May; 44(5):1928-32. PubMed ID: 6546897
[TBL] [Abstract][Full Text] [Related]
3. Studies on the biochemical mechanism of the novel antitumor agent, CI-920.
Fry DW; Boritzki TJ; Jackson RC
Cancer Chemother Pharmacol; 1984; 13(3):171-5. PubMed ID: 6548419
[TBL] [Abstract][Full Text] [Related]
4. Transport of the antitumor antibiotic Cl-920 into L1210 leukemia cells by the reduced folate carrier system.
Fry DW; Besserer JA; Boritzki TJ
Cancer Res; 1984 Aug; 44(8):3366-70. PubMed ID: 6547636
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152).
Fujimoto K; Oka T; Morimoto M
Cancer Res; 1987 Mar; 47(6):1516-22. PubMed ID: 2434218
[TBL] [Abstract][Full Text] [Related]
6. In vitro DNA strand scission and inhibition of nucleic acid synthesis in L1210 leukemia cells by a new class of DNA complexers, the anthra[1,9-cd]pyrazol-6(2H)-ones (anthrapyrazoles).
Fry DW; Boritzki TJ; Besserer JA; Jackson RC
Biochem Pharmacol; 1985 Oct; 34(19):3499-508. PubMed ID: 2413861
[TBL] [Abstract][Full Text] [Related]
7. Novel antitumor agents CI-920, PD 113,270 and PD 113,271. I. Taxonomy, fermentation and biological properties.
Tunac JB; Graham BD; Dobson WE
J Antibiot (Tokyo); 1983 Dec; 36(12):1595-600. PubMed ID: 6689323
[TBL] [Abstract][Full Text] [Related]
8. 1,4-Anthraquinone: an anticancer drug that blocks nucleoside transport, inhibits macromolecule synthesis, induces DNA fragmentation, and decreases the growth and viability of L1210 leukemic cells in the same nanomolar range as daunorubicin in vitro.
Perchellet EM; Magill MJ; Huang X; Dalke DM; Hua DH; Perchellet JP
Anticancer Drugs; 2000 Jun; 11(5):339-52. PubMed ID: 10912950
[TBL] [Abstract][Full Text] [Related]
9. Biochemical pharmacology of the lipophilic antifolate, trimetrexate.
Jackson RC; Fry DW; Boritzki TJ; Besserer JA; Leopold WR; Sloan BJ; Elslager EF
Adv Enzyme Regul; 1984; 22():187-206. PubMed ID: 6236675
[TBL] [Abstract][Full Text] [Related]
10. Antimycotic effects of the novel antitumor agents fostriecin (CI-920), PD 113,270 and PD 113,271.
Mamber SW; Okasinski WG; Pinter CD; Tunac JB
J Antibiot (Tokyo); 1986 Oct; 39(10):1467-72. PubMed ID: 3781915
[TBL] [Abstract][Full Text] [Related]
11. Biochemical pharmacology and experimental chemotherapy studies with guanine-7-oxide, a novel purine antibiotic.
Jackson RC; Boritzki TJ; Besserer JA; Hamelehle KL; Shillis JL; Leopold WR; Fry DW
Adv Enzyme Regul; 1987; 26():301-16. PubMed ID: 3673707
[TBL] [Abstract][Full Text] [Related]
12. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.
Jackman AL; Taylor GA; Gibson W; Kimbell R; Brown M; Calvert AH; Judson IR; Hughes LR
Cancer Res; 1991 Oct; 51(20):5579-86. PubMed ID: 1913676
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics.
Fujimoto S; Ogawa M
Cancer Chemother Pharmacol; 1982; 8(2):157-62. PubMed ID: 7105379
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of spergualin, a novel antitumor antibiotic.
Nishikawa K; Shibasaki C; Takahashi K; Nakamura T; Takeuchi T; Umezawa H
J Antibiot (Tokyo); 1986 Oct; 39(10):1461-6. PubMed ID: 3781914
[TBL] [Abstract][Full Text] [Related]
15. Biological and biochemical activities of the novel antitumor antibiotic PD 114,759 and related derivatives.
Fry DW; Shillis JL; Leopold WR
Invest New Drugs; 1986; 4(1):3-10. PubMed ID: 3754542
[TBL] [Abstract][Full Text] [Related]
16. Structure and activity relationship of several novel CC-1065 analogs.
Li LH; Wallace TL; DeKoning TF; Warpehoski MA; Kelly RC; Prairie MD; Krueger WC
Invest New Drugs; 1987 Dec; 5(4):329-37. PubMed ID: 3436738
[TBL] [Abstract][Full Text] [Related]
17. Activity of the thymidylate synthase inhibitor 2-desamino-N10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo.
Jackman AL; Taylor GA; O'Connor BM; Bishop JA; Moran RG; Calvert AH
Cancer Res; 1990 Sep; 50(17):5212-8. PubMed ID: 2386929
[TBL] [Abstract][Full Text] [Related]
18. Experimental pharmacology of auromomycin in L1210 tumor cells in vitro and in vivo.
Samy TS; Siegel PJ; Hopper WE; Krishan A
Cancer Res; 1984 Aug; 44(8):3202-7. PubMed ID: 6589039
[TBL] [Abstract][Full Text] [Related]
19. In vivo and in vitro anticancer activity of the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog (PD 114,721).
Roberts BJ; Hamelehle KL; Sebolt JS; Leopold WR
Cancer Chemother Pharmacol; 1986; 16(2):95-101. PubMed ID: 3081269
[TBL] [Abstract][Full Text] [Related]
20. Effects of new N-alkyl analogues of adriamycin on in vitro survival and cell cycle progression of L1210 cells.
Traganos F; Israel M; Silber R; Seshadri R; Kirschenbaum S; Potmesil M
Cancer Res; 1985 Dec; 45(12 Pt 1):6273-9. PubMed ID: 4063977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
